Posts tagged ‘Melanoma Market Analysis’

Zelboraf (vemurafenib) approved in metastatic melanoma

August 25th, 2011

Daedalus

Last week the hot news was the anticipated FDA approval of vemurafenib (Zelboraf™) in metastatic melanoma for patients with BRAF V600E mutations.

Sally Church on Pharma Strategy Blog has written extensively about new products in development for metastatic melanoma. As Sally notes in her recent blog post discussing the Zelboraf™ approval:

“the good news is that oncologists now have two new agents for treatment in 2011, which is very much a grand cru year for melanoma.”

A little known fact is that Sally is a former finalist in the UK Daily Telegraph newspaper’s wine taster of the year competition, so it is perhaps not surprising to see some wine references in her writing.

If you are interested in the price of Zelboraf™ – you can find it on Pharma Strategy Blog where Sally analyses the cost of a course of treatment and compares this to the price for ipilimumab.

Pieter Droppert’s write-up of the 2011 ASCO annual meeting plenary data on metastatic melanoma was recently published in the august issue of Pharmacy Today.

Metastatic Melanoma Competitor and Market Analysis

May 13th, 2011

Daedalus

One of the services that Icarus Consultants offers is to monitor competitor activity in a market, therapeutic area or pathway, and advise clients on new developments.

For those interested in metastatic melanoma, this week saw Roche/Genentech make marketing applications to the FDA in the United States and European EMEA for PLX4032 (vemurafenib) in BRAF V600E mutation-positive metastatic melanoma.

Sally Church on Pharma Strategy Blog has more about the Roche/Genentech filing, and has written extensively about BRAF inhibitors and mechanisms of resistance.

If you are interested in learning more about how Icarus Consultants can help you keep track of competitor activity in a pharma market, business or therapeutic area, please contact us.